Immutep Ltd has released a press release.
AIPAC-003 safety lead-in data presented at ESMO Breast 2024
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Positive initial data in phase 2 Soft Tissue Sarcoma trial
- Positive preliminary topline results from TACTI-003 Cohort B
- CHDR to conduct first-in-human phase 1 trial of IMP761
- First Clinical Data announced from 90mg Dosing of Efti
- PEI provides constructive feedback for ph3 lung cancer trial
Later from Immutep
- A$100 million fully underwritten equity raising
- Immutep Capital Raising Presentation
- Immutep announces Ph 3 clinical trial collaboration with MSD
- Immutep completes institutional pro-rata offer & placement
- Immutep completes underwritten retail entitlement offer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep